Evidence map›Paper›PMID 41366993›Full record

ArticleMedicine2025

Recurrent severe COVID-19 with Good's syndrome in a patient after thymoma surgery: A case report.

Hao Zhang, Huan Liu

Abstract readCase Reports
In one paragraph

Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hao ZhangDepartment of Respiratory, Shenyang Tenth People's Hospital, Shenyang Chest Hospital, Shenyang, China.ORCID 0009-0006-6558-4790

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleGood's syndrome (GS) is a rare adult-onset immunodeficiency characterized by the coexistence of thymoma and profound defects in both humoral and cellular immunity. Because of these immune abnormalities, patients are highly vulnerable to recurrent and severe infections, such as COVID-19. However, clinical data on the course and management of COVID-19 in GS remain scarce. This case report aims to describe a patient with recurrent severe COVID-19 following thymectomy and to highlight the diagnostic and therapeutic importance of early immunologic evaluation and intravenous immunoglobulin (IVIG) therapy in this context. PATIENT CONCERNS: A 60-year-old man with a history of thymoma resection presented with recurrent episodes of severe COVID-19 pneumonia, each necessitating hospitalization and oxygen therapy. Despite antiviral and corticosteroid treatment, his condition worsened, with persistent hypoxemia and progressive lung infiltrates. Immunologic workup revealed near-complete B-cell depletion and reduced CD4 + T-cell counts, leading to a diagnosis of GS. DIAGNOSIS: GS following thymoma resection, presenting with recurrent severe COVID-19 complicated by bacterial superinfection.

interventionsThe patient received antiviral agents, corticosteroids, and broad-spectrum antibiotics across multiple hospitalizations. After diagnosis, IVIG therapy was initiated. OUTCOMES: IVIG administration led to rapid clinical stabilization and marked radiographic improvement. The patient remained free of relapse during follow-up. LESSONS: This case highlights the importance of early immunologic assessment in patients with atypical or recurrent viral infections post-thymectomy. Prompt recognition of GS and initiation of IVIG therapy can be critical to achieving favorable outcomes.

Indexed as

COVID-19Immunologic Deficiency SyndromesThymectomyThymomaThymus NeoplasmsAntiviral AgentsHumansImmunoglobulins, IntravenousMaleMiddle AgedRecurrenceSARS-CoV-2Antiviral AgentsImmunoglobulins, Intravenouscase reportCOVID-19Good’s syndromeimmunodeficiencyrecurrent infectionthymoma

Identifiers

PMID41366993
PMCPMC12688821

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.